SEPTInvestingStart Free

ENGN 8-K: Fda approval

enGene Therapeutics

Filed with the SEC on · accession 0001193125-26-456703

ENGN filed a 8-K (current report) with the SEC on Nov 12, 2026. enGene Therapeutics announced positive results from the pivotal Cohort 1 of its Phase 2 LEGEND trial of detalimogene and alignment with the FDA on key components of the planned Biologics License Application (BLA).

Summary of the filing

enGene Therapeutics announced positive results from the pivotal Cohort 1 of its Phase 2 LEGEND trial of detalimogene and alignment with the FDA on key components of the planned Biologics License Application (BLA). The company also provided preliminary financial information, expecting approximately $245.8 million in cash, cash equivalents, and marketable securities as of October 31, 2026.

For details, click here →How to read a 8-K →

Key details

Cash, cash equivalents, and marketable securities as of October 31, 2026$245.8M
RegistrantenGene Therapeutics Inc.
AuditorKPMG LLP

✦ Ask GOAX AI about this filing — what it means for ENGN, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ENGN?

Click here

Frequently asked questions

What did ENGN file with the SEC on Nov 12, 2026?

ENGN filed a 8-K (Fda approval). enGene Therapeutics announced positive results from the pivotal Cohort 1 of its Phase 2 LEGEND trial of detalimogene and alignment with the FDA on key components of the planned Biologics License Application (BLA). The company also provided preliminary financial information, expecting approximately $245.8 million in cash, cash equivalents, and marketable securities as of October 31, 2026.

What does a fda approval mean for ENGN stock?

For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other ENGN SEC filings

Get alerts when ENGN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
ENGN overviewENGN analysisENGN newsLatest SEC filings